Company intelligence / Profile preview

Seneca

Philadelphia, Pennsylvania, United States

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Seneca Therapeutics is developing SVV-001, an oncolytic Seneca Valley Virus engineered as an immunotherapeutic for TEM8-positive solid tumors. SVV-001 previously showed an excellent safety record and evidence of efficacy in Phase 1/2 trials under a prior company, and Seneca Therapeutics is initiating Phase 2 studies in patients with neuroendocrine tumors, including small cell lung cancer.[5][10][11]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Oncolytic virus therapyViral vectorVaccineBiologic
Industry: Biotech

Partnerships

Planned/strategic business development partnership in immuno-oncology (mentioned generally, not yet named)[5][11]

Beyond the preview

Go deeper on Seneca.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seneca.

Explore the full profile